Arafat May Be Suffering From Leukemia

[drdon326]

Leukemia specialists examined ailing Palestinian leader Yasser Arafat at a French military hospital to determine whether he suffers from the blood cancer, Palestinian officials said Saturday. Early test results were expected by Saturday evening. "Within 24 to 48 hours, we should know what he's facing," said top Arafat aide Nabil Abu Rdeneh.

The 75-year-old Arafat has been sick for two weeks and blood tests have revealed he has a low platelet count - a possible symptom of leukemia, other cancers or a number of other maladies.

Arafat received a transfusion of platelets shortly after being rushed Friday from his headquarters in Ramallah to France for treatment at the Hopital d'Instruction des Armees de Percy, a military teaching hospital southwest of Paris that specializes in blood disorders and trauma care.

A Palestinian official, speaking on condition of anonymity, said there was a strong possibility that Arafat was suffering from leukemia and that a team of French physicians specializing in the disorder had examined the Palestinian leader on Friday.

http://www.washingtonpost.com/wp-dyn/articles/A11421-2004Oct30.html

...................................................................

[drdon326]

1. 10 miles away.....Hadassah Hospital has huge Heme-Onc Dept.

Leukemia and Lymphoma

Editor: Aaron Polliack, Head of Lymphoma-Leukemia Unit,
Department of Haematology, Hadassah University Hospital,
Israel

Publication Details:
Volume 43, 2002, 12 issues per year
ISSN: 1042-8194

...............................................................

[drdon326]

2. Blood, Vol. 91 No. 3 (February 1), 1998: pp. 756-763

Nonmyeloablative Stem Cell Transplantation and Cell Therapy as an Alternative to Conventional Bone Marrow Transplantation With Lethal Cytoreduction for the Treatment of Malignant and Nonmalignant Hematologic Diseases


By Shimon Slavin, Arnon Nagler, Ella Naparstek, Yossi Kapelushnik, Memet Aker, Gabriel Cividalli, Gabor Varadi, Mark Kirschbaum, Aliza Ackerstein, Simcha Samuel, Avraham Amar, Chaim Brautbar, Ofira Ben-Tal, Amiram Eldor, and Reuven Or

From The Departments of Bone Marrow Transplantation and The Cancer Immunotherapy & Immunobiology Research Center, Pediatrics, and Tissue Typing Unit, Hadassah University Hospital, Jerusalem; and the Division of Hematology, the Department of Medicine, Ichilov Hospital, Tel Aviv, Israel.

http://www.bloodjournal.org/cgi/content/full/91/3/756